064 Early Clinical Score Changes Predict Additional Treatment Necessity In Pemphigus/Pemphigoid

Current guidelines recommend that the disease severity and treatment efficacy should be evaluated with clinical scores in pemphigus/pemphigoid. PDAI pemphigus BPDAI pemphigoid are widely used to determine whether additional second-line therapies (e.g., plasma change) considered if initial is insufficient for control. To validate utility of monitoring PDAI/BPDAI transitions, we retrospectively analysed 67 47 patients who received therapy dermatology department an institute Japan. We score ratios day7/ day0 day14/ day0. In comparison between groups needed (Group B) or not A), were significantly decreased Group A compared B: 0.548 vs 0.761 PDAI, 0.565 0.901 (erosion/blister: E/B), 0.350 0.760 (urticaria/erythema: U/E), respectively (p<0.05). The (E/B) also reduced B, (0.250 0.621 0.172 0.607, respectively, p<0.05). focused analysis on severe cases because there was no significant difference B before treatments. (U/E) day 7/day0 (0.556 vs. 0.781, 0.661 0.907 0.268 0.820, (0.222 0.641 0.256 0.642, p<0.01). Our results indicate transitions possible early predictors necessity during phase.